Nephros, Inc. (NEPH) trades at a trailing P/E of 25.3, forward P/E of 51.8. Trailing earnings yield is 3.95%, forward earnings yield 1.93%. PEG 0.02 (Peter Lynch undervalued ≤1.0). Graham Number is $1.56.
Criteria proven by this page:
Overall SharesGrow Score: 76/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.9 | 0.20 | 26.95 | 7.75 | - |
| 2017 | -29.4 | 0.39 | 12.22 | 6.25 | - |
| 2018 | -10.3 | -0.04 | 9.25 | 6.18 | - |
| 2019 | -21.9 | 1.37 | 16.05 | 7.26 | - |
| 2020 | -16.3 | -0.69 | 6.22 | 9.10 | - |
| 2021 | -14.4 | 0.68 | 5.05 | 5.78 | - |
| 2022 | -1.6 | -0.02 | 2.14 | 1.20 | - |
| 2023 | -22.8 | 0.29 | 4.30 | 2.52 | - |
| 2024 | 209.1 | -2.00 | 1.80 | 1.09 | - |
| 2025 | 43.4 | 0.03 | 5.08 | 2.76 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.56 | $2.32M | $-3.03M | -130.7% |
| 2017 | $-0.14 | $3.81M | $-809K | -21.2% |
| 2018 | $-0.50 | $5.69M | $-3.4M | -59.8% |
| 2019 | $-0.42 | $10.33M | $-3.18M | -30.8% |
| 2020 | $-0.52 | $8.56M | $-4.77M | -55.7% |
| 2021 | $-0.41 | $10.22M | $-4.11M | -40.2% |
| 2022 | $-0.71 | $9.98M | $-4.55M | -45.6% |
| 2023 | $-0.15 | $14.24M | $-1.58M | -11.1% |
| 2024 | $0.01 | $14.16M | $74K | 0.5% |
| 2025 | $0.11 | $18.79M | $1.19M | 6.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.06 | $0.06 – $0.06 | $20.49M | $20.17M – $20.81M | 2 |
| 2027 | $0.13 | $0.13 – $0.13 | $22.86M | $22.7M – $23.03M | 1 |
